Cubist Systematic Strategies LLC Buys Shares of 15,278 Astria Therapeutics, Inc. (NASDAQ:ATXS)

Cubist Systematic Strategies LLC bought a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,278 shares of the biotechnology company’s stock, valued at approximately $137,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new position in Astria Therapeutics in the fourth quarter valued at about $50,000. Northern Trust Corp raised its position in shares of Astria Therapeutics by 4.5% in the fourth quarter. Northern Trust Corp now owns 458,234 shares of the biotechnology company’s stock valued at $4,097,000 after purchasing an additional 19,893 shares during the period. Virtus ETF Advisers LLC bought a new stake in shares of Astria Therapeutics in the fourth quarter valued at approximately $65,000. Voya Investment Management LLC raised its position in shares of Astria Therapeutics by 367.4% in the fourth quarter. Voya Investment Management LLC now owns 71,708 shares of the biotechnology company’s stock valued at $641,000 after purchasing an additional 56,366 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Astria Therapeutics by 19.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 2,878 shares during the period. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. JMP Securities assumed coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $47.00 price target on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $30.00.

Astria Therapeutics Trading Down 0.8%

Astria Therapeutics stock opened at $3.96 on Monday. The firm’s 50 day simple moving average is $5.01 and its 200 day simple moving average is $7.34. The firm has a market capitalization of $223.48 million, a PE ratio of -1.89 and a beta of 0.45. Astria Therapeutics, Inc. has a 1-year low of $3.56 and a 1-year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). Research analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.